Evidence map›Paper›PMID 33235810›Full record

ArticleFuture science OA2020

Improving of psychological status and inflammatory biomarkers during omalizumab for chronic spontaneous urticaria.

Laura Diluvio, Arianna Piccolo, Francesco Marasco, Laura Vollono, Caterina Lanna, Barbara Chiaramonte, Cinzia Niolu, Elena Campione, Luca Bianchi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future science OA, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Modulation of Mast Cell Activation via MRGPRX2 by Natural Oat Extract.International journal of molecular sciences · 2025
    Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Laura DiluvioDermatology, Department of Systems Medicine, University of Rome Tor Vergata, Viale Oxford, Rome 81 00133, Italy.ORCID https://orcid.org/0000-0003-1844-9052
Arianna PiccoloDermatology, Department of Systems Medicine, University of Rome Tor Vergata, Viale Oxford, Rome 81 00133, Italy.
Francesco MarascoPsychiatry, Department of Systems Medicine, University of Rome Tor Vergata, Viale Oxford, Rome 81 00133, Italy.
Laura VollonoDermatology, Department of Systems Medicine, University of Rome Tor Vergata, Viale Oxford, Rome 81 00133, Italy.
Caterina LannaDermatology, Department of Systems Medicine, University of Rome Tor Vergata, Viale Oxford, Rome 81 00133, Italy.
Barbara ChiaramonteINAIL, Actuarial-Statistic consultancy office, via Stefano Gradi, Rome 55 00143, Italy.
Cinzia NioluPsychiatry, Department of Systems Medicine, University of Rome Tor Vergata, Viale Oxford, Rome 81 00133, Italy.
Elena CampioneDermatology, Department of Systems Medicine, University of Rome Tor Vergata, Viale Oxford, Rome 81 00133, Italy.
Luca BianchiDermatology, Department of Systems Medicine, University of Rome Tor Vergata, Viale Oxford, Rome 81 00133, Italy.
University of Rome Tor Vergata · ITIstituto Nazionale di Statistica · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDepression and anxiety are the most common psychiatric comorbidities in chronic spontaneous urticaria (CSU). Omalizumab is a monoclonal antibody approved for CSU treatment. We evaluated the prevalence of anxiety and depression in CSU patients before and after treatment with omalizumab. MATERIALS &

methodsA total of 30 patients were enrolled in the study: 15 patients affected by CSU and treated with omalizumab and the other 15 healthy subjects did not receive any systemic therapy. All patients were evaluated using Hospital Anxiety and Depression Scale, CRP and erythrocyte sedimentation rate, at baseline and after 6 months.

resultsThe omalizumab group after 6 months of therapy had a decrease of all the scores and biomarkers.

conclusionOmalizumab allowed an improvement of urticaria and mental comorbidities.

Indexed as

anxietychronic spontaneous urticariaCSUdepressionDLQIH1-anti-histamineHADSHospital Anxiety and Depression Scaleomalizumabpsychiatric disordersUAS7

Identifiers

PMID33235810
PMCPMC7668119
OpenAlexW3048722470

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.